Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib

Australasian Journal of Dermatology

Volumn 55, Issue 4, 2014, Pages 250-254

  Anforth, Rachael ^a,b   Liu, Michael ^a   Nguyen, Bao ^b   Uribe, Pablo ^a,c   Kefford, Richard ^b,d,e   Clements, Arthur ^b,d   Long, Georgina V ^b,d,e   Fernandez Peñas, Pablo ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MELANOMA INSTITUTE AUSTRALIA   (Australia)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

acneiform eruption; BRAF inhibitor; dabrafenib; MEK inhibitor; melanoma; trametinib

Indexed keywords

CLINDAMYCIN; DABRAFENIB; DOXYCYCLINE; TRAMETINIB; TRICLOSAN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; TOPICAL ANTIINFECTIVE AGENT;

ACNE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; PAPULE; PUSTULE; RETROSPECTIVE STUDY; TREATMENT WITHDRAWAL; ACNEIFORM ERUPTIONS; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); CUTANEOUS DRUG ADMINISTRATION; DRUG ERUPTIONS; MELANOMA; MIDDLE AGED; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ACNEIFORM ERUPTIONS; ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINDAMYCIN; CLINICAL TRIALS AS TOPIC; DOXYCYCLINE; DRUG ERUPTIONS; FEMALE; HUMANS; IMIDAZOLES; MALE; MELANOMA; MIDDLE AGED; OXIMES; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TRICLOSAN;

EID: 84911438827     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/ajd.12124     Document Type: Article

References (22)

1. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 2012; 367: 107-114.
2. Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13: 782-789.
3. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 2013; 31: 482- 9.
4. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012; 367: 1694-1703.
5. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 2011; 29: 1239-1246.
6. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118: 4014-4023.
7. Thomas NE, Edmiston SN, Alexander A, et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol. Biomarkers Prev. 2007; 16: 991-997.
8. Liu W, Kelly JW, Trivett M, et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J. Invest. Dermatol. 2007; 127: 900-905.
9. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008; 5: e120.
10. Tomkova H, Kohoutek M, Zabojnikova M, et al. Cetuximab-induced cutaneous toxicity. J. Eur. Acad. Dermatol. Venereol. 2010; 24: 692-696.
11. Tan AR, Steinberg SM, Parr AL, et al. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. Ann. Oncol. 2008; 19: 185-190.
12. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005; 6: 491-500.
13. Fleta-Asin B, Vano-Galvan S, Ledo-Rodriguez A, et al. Facial acneiform rash associated with sorafenib. Dermatol. Online J. 2009; 15: 7.
14. Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br. J. Dermatol. 2012; 167: 1153-1160.
15. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012; 366: 707-714.
16. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011; 364: 2507-2516.
17. Smith TM, Gilliland K, Clawson GA, et al. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J. Invest. Dermatol. 2008; 128: 1286-1293.
18. Birch K, MacLaren D, George K,. Sports and Exercise Physiology. Abington: BIOS Scientific Publishers, 2005.
19. Ropper AH, Samuels MA,. Adams & Victor's Principles of Neurology, 9th edn. New York: McGraw-Hill, 2009.
20. Wyss M, Kaddurah-Daouk R,. Creatine and creatinine metabolism. Physiol. Rev. 2000; 80: 1107-1213.
21. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support. Care Cancer 2011; 19: 1079-1095.
22. Zimmer L, Vaubel J, Livingstone E, et al. Side effects of systemic oncological therapies in dermatology. J. Dtsch. Dermatol. Ges. 2012; 10: 475-486.